Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

被引：3

作者：

Toribio-Garcia, Irene ^{[1
]}

Olivares-Hernandez, Alejandro ^{[2
,3
]}

Miramontes-Gonzalez, Jose Pablo ^{[4
,5
]}

Dominguez, Luis Posado ^{[2
,3
]}

Garcia, Ana Martin ^{[3
,6
]}

Bachiller, Rocio Eiros ^{[3
,6
]}

Figuero-Perez, Luis ^{[2
,3
]}

Martinez, Maria Garijo ^{[2
,3
]}

Ruiz, Jonnathan Roldan ^{[2
,3
]}

Hernandez, Lorena Bellido ^{[2
,3
,7
]}

Fonseca-Sanchez, Emilio ^{[2
,3
,7
]}

Sanchez, Pedro Luis ^{[3
,6
,7
]}

del Barco-Morillo, Edel ^{[2
,3
,7
]}

机构：

[1] Univ Hosp Leon, Dept Cardiol, Leon 24008, Spain

[2] Univ Hosp Salamanca, Dept Med Oncol, Salamanca 37007, Spain

[3] Inst Biomed Res Salamanca IBSAL, Salamanca 37007, Spain

[4] Univ Hosp Rio Hortega, Dept Internal Med, Valladolid 47012, Spain

[5] Univ Valladolid, Dept Med, Valladolid 45005, Spain

[6] Univ Hosp Salamanca, Dept Cardiol, Salamanca 37007, Spain

[7] Univ Salamanca, Dept Med, Salamanca 37007, Spain

来源：

CANCERS | 2023年 / 15卷 / 17期

关键词：

immunotherapy; immune checkpoint inhibitors; elderly; cardiotoxicity; real-word data;

D O I：

10.3390/cancers15174293

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Immunotherapy is the mainstay treatment for most solid tumours. However, its cardiotoxicity is not yet known and studied, and its uncertainty is even greater in elderly patients. For this reason, this ambispective study was conducted in 195 patients over 70 years of age who were treated with immunotherapy. The percentage of patients with cardiotoxicity was 1.54%; 1.35% of patients with previous heart disease were diagnosed with cardiotoxicity, and 1.65% of those without previous heart disease were diagnosed with cardiotoxicity. The median time from the initiation of treatment until the cardiac event was 45 days. The most frequent toxicity was myocarditis, which was identified in 66.7% of patients, followed by arrhythmias in 33.3% of patients. In conclusion, immunotherapy is shown to be a safe treatment in elderly cancer patients in terms of cardiotoxicity.Abstract Introduction: Immunotherapy represents a key pillar of cancer treatments, with high response rates and long survival. Its use is increasing, mainly at the expense of the geriatric population due to the ageing of this population. However, despite its benefit, its safety in certain areas such as cardiotoxicity is largely unknown. The aim of this study is to assess the safety of immunotherapy in elderly patients using real-world data. Methods: This is an ambispective study of patients & GE; 70 years old with solid tumours who were treated with immunotherapy at the University Hospital of Salamanca. Cardiotoxicity was assessed using the CTCAEv5.0 criteria. Results: In total, 195 patients were included (76.9% male and 23.1% female), with a mean age of 75 years [70-93]. The percentage of patients with cardiotoxicity was 1.54%; 1.35% of patients with previous heart disease were diagnosed with cardiotoxicity, and 1.65% of those without previous heart disease were diagnosed with cardiotoxicity. The median time from the initiation of treatment until the cardiac event was 45 days [14-96]. The most frequent toxicity was myocarditis in 66.7% of patients, followed by arrhythmias in 33.3% of patients. Conclusions: Immunotherapy is shown to be a safe treatment in elderly cancer patients in terms of cardiotoxicity. The event rate shows no difference between patients with or without cardiac comorbidity.

引用

页数：10